The subsequent chapters will be dedicated to specific aspects of renal disease and DNA methylation, which are relevant to: (I) anemia and erythropoietin in CKD (II) metabolic and biochemical aspects (e.g., hyperhomocysteinemia (HHcy), a strong cardiovascular risk factor with high prevalence in CKD. This evidence concerns the gene EPO and chronic kidney disease.